BioPharma CreditLSE:BPCR +0.63%49 EV-to-FCF is 11.69 as of Jul. 02, 2026, which is 22% above its 10-year median of 9.61. GuruFocus rates LSE:BPCR with a GF Score™ of 49/100 and a GF Value™ of $0.97 (Fairly Valued). The stock has 2 warning signs investors should review. Among 935 Asset Management companies, BioPharma Credit ranks better than 59.25% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BioPharma Credit's Enterprise Value is $1,064.7 Mil.
BioPharma Credit's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $91.1 Mil. Therefore, BioPharma Credit's EV-to-FCF for today is 11.69.
The historical rank and industry rank for BioPharma Credit's EV-to-FCF or its related term are showing as below:
LSE:BPCR'
s EV-to-FCF Range Over the Past 10 Years
Min: 5.39 Med: 9.61 Max: 20.33
Current: 11.71
During the past 9 years, the highest EV-to-FCF of BioPharma Credit was 20.33. The lowest was 5.39. And the median was 9.61.
LSE:BPCR's EV-to-FCF is ranked better than 59.25% of 935
companies
in the Asset Management industry
Industry Median: 14.54
vs LSE:BPCR: 11.71
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioPharma Credit's PE Ratio (TTM) for today is calculated as:
BioPharma Credit's share price for today is $0.96.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioPharma Credit's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.114.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BioPharma Credit EV-to-FCF Related Terms
BioPharma Credit EV-to-FCF Historical Data
* Premium members only.
The historical data trend for BioPharma Credit's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, BioPharma Credit's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioPharma Credit EV-to-FCF vs Asset Management Industry
For the Asset Management industry and Financial Services sector, BioPharma Credit's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where BioPharma Credit's EV-to-FCF falls into.
BioPharma Credit's current Enterprise Value is $1,064.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioPharma Credit's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $91.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioPharma Credit (LSE:BPCR) has a EV-to-FCF of 11.69 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BioPharma Credit and its competitors. This is 22% above median its historical median of 9.61. Over the past decade, BioPharma Credit's EV-to-FCF has ranged from 5.39 to 20.33. According to the industry distribution chart, BioPharma Credit ranks #381 out of 935 companies in the Asset Management industry, placing it in the top 40.7%.
Is BioPharma Credit's EV-to-FCF too high?
BioPharma Credit's current EV-to-FCF of 11.69 is 22% above median its 10-year median of 9.61. Over the past 10 years, this metric has ranged from a low of 5.39 to a high of 20.33. The Asset Management industry median EV-to-FCF is 14.54. BioPharma Credit's value of 11.69 is 19.6% below this industry median. Based on the distribution chart, BioPharma Credit ranks #381 out of 935 companies in the Asset Management industry, which is above the industry midpoint. Overall, BioPharma Credit has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's EV-to-FCF compare to BLK and BX?
According to the Asset Management industry distribution chart, BioPharma Credit ranks #381 out of 935 companies for EV-to-FCF. This puts BioPharma Credit in the upper half of its industry. The industry median EV-to-FCF is 14.54. BioPharma Credit's value of 11.69 is 19.6% below this benchmark. Historically, BioPharma Credit's own EV-to-FCF has ranged from 5.39 to 20.33 over the past decade. While the company's 10-year median is 9.61 vs. the industry median of 14.54, BioPharma Credit has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for an Asset Management company?
The median EV-to-FCF among Asset Management companies is 14.54, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioPharma Credit's current EV-to-FCF of 11.69 is 19.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BioPharma Credit and its competitors. For the Asset Management industry, the median EV-to-FCF is 14.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioPharma Credit's current EV-to-FCF is 11.69, which is 22% above median its own 10-year median of 9.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.97, compared to a current price of $0.96 — trading 1% below its estimated fair value. The current EV-to-FCF is 11.69, which is 22% above median its 10-year median of 9.61 and 19.6% below the Asset Management industry median of 14.54. BioPharma Credit's overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current EV-to-FCF is 11.69 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?
Based on GuruFocus' analysis, BioPharma Credit stock appears to be undervalued.
The current stock price of $0.96 is trading 1% below its estimated GF Value™ of $0.97.
GuruFocus considers BioPharma Credit to be Fairly Valued.
Key valuation signals for LSE:BPCR:
EV-to-FCF: 11.69 (22% above median its 10-year median of 9.61)
GF Value™: $0.97 vs. price of $0.96 (1% below fair value)
Industry Position: 19.6% below the Asset Management median (#381 of 935)
No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
49GF Score
Get the complete analysis for LSE:BPCR
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BPCR has been successfully added to your 
